21 CFR 314.70 reporting routes for approved drug changes
21 CFR 314.70 sets PAS, CBE-30, CBE-0 and annual report routes for approved drug changes. Learn when distribution can start and how ANDAs fit the rule.
21 CFR 314.70 tells an NDA holder how to report a change: prior approval before distribution for a major change, CBE-30 for a moderate change, CBE-0 on FDA receipt for listed moderate categories, and the next annual report for a minor change. Section 314.97 applies that same framework to an approved ANDA.
The test is the potential adverse effect on identity, strength, quality, purity or potency as those factors relate to safety or effectiveness. Cost, or calling the change small, does not pick the route. The distribution rule is in 21 CFR 314.70(b)-(d).
Reporting changes to an approved NDA or ANDA
The regulation sets three risk tiers: substantial, moderate and minimal adverse-effect potential. CBE-30 and eligible CBE-0 changes both sit in the moderate tier, paragraph (c). CBE-0 is not a fourth risk level.
| Reporting route | Basis | Earliest distribution under this framework |
|---|---|---|
| Prior approval supplement (PAS) | Major change with substantial adverse-effect potential | After FDA approves the supplement |
| CBE-30 | Moderate adverse-effect potential | Ordinarily at least 30 days after FDA receives the supplement, subject to FDA intervention |
| CBE-0 | Eligible categories in paragraph (c)(6) | Upon FDA receipt of the supplement |
| Annual report | Minor change with minimal adverse-effect potential | No pre-distribution supplement waiting period under paragraph (d); report in the next annual report |
The table follows section 314.70(b)(1), (b)(3), (c)(1), (c)(4)-(6) and (d)(1). CBE-30 and CBE-0 are shorthand for the changes-being-effected-in-30-days designation and the immediate changes-being-effected designation. Search the section for those labels and you will not find them. FDA receipt, rather than applicant dispatch, controls the CBE timing.
Before distributing a drug product made with a manufacturing change, the applicant must assess that change's effects. That assessment still applies when the manufacturing change is reported in the annual report. The assessment duty is tied to the manufacturing change, not to every item that later appears in the annual report. The applicant must also notify FDA about each change to an approved condition beyond variations already provided for in the application. If a regulation or guidance provides a less burdensome notice for a paragraph (b) or (c) change, the applicant must use that notice. The regulation's examples are a supplement that does not require approval before distribution, and an annual report. Section 314.70(a) sets these duties.
When a prior approval supplement is required
A major change has substantial potential to adversely affect the specified product characteristics. Under section 314.70(b), examples include:
- Formulation changes, except those covered by paragraphs (c) or (d).
- Changes requiring equivalence studies under part 320.
- Changes that could affect sterility assurance.
- Drug-substance synthesis or manufacturing changes that could affect impurity profiles or physical, chemical or biological properties.
Most labeling changes also require prior approval unless an identified exception applies. Not every formulation, process or labeling change has the same category, so read the conditions in section 314.70(b)(2) before you assign one.
The PAS restriction in section 314.70(b)(3) is approval before distribution of the changed product. It does not say approval must precede every manufacturing activity.
How the CBE-30 waiting period works
For CBE-30, the clock starts when FDA receives the supplement. The submission must explain the change's basis, state the intended change date and include the required supporting information. Distribution can ordinarily begin after the prescribed period while approval remains pending. Section 314.70(c)(3)-(4) sets these requirements.
Waiting 30 days does not always allow distribution. If FDA gives notice within 30 days that prior approval is required, distribution must wait for approval. If FDA instead identifies missing required information within that period, the applicant must not distribute until it amends the supplement to provide it. Don't assume every amendment starts a new 30-day clock. Paragraph (c)(5) does not say an amendment starts one. Follow the notice FDA actually sends.
Passing 30 days is not FDA approval. If FDA later disapproves the supplemental NDA, it may order distribution to stop for product made with the manufacturing change under section 314.70(c)(7). Section 314.97 makes that section apply to an approved ANDA.
Which changes qualify for CBE-0?
CBE-0 is limited to eligible categories. A claimed quality improvement does not, by itself, justify immediate distribution. Paragraph (c)(6) includes additions to specifications or changes to methods or controls that increase assurance of product characteristics.
It also includes a change in the size and/or shape of a container for a nonsterile product, except a solid dosage form. The change must not alter the labeled amount of drug product or move from one container-closure system to another. Check all the conditions in paragraph (c)(6)(ii) before applying this category.
Safety labeling has separate conditions
The CBE labeling provision covers specified changes reflecting newly acquired information. Eligible purposes include adding or strengthening a contraindication, warning, precaution or adverse reaction when the evidence of a causal association meets the standard for inclusion in the labeling under section 201.57(c). They also include adding or strengthening a statement about drug abuse, dependence, psychological effect or overdosage, and adding or strengthening a dosage-and-administration instruction intended to increase safe use. Deleting false, misleading or unsupported indications for use or claims for effectiveness is covered. So is a labeling change that would normally need prior approval, if FDA specifically asks for it under this provision. Section 314.70(c)(6)(iii) gives the conditions. It is not a general route for adding indications.
"Newly acquired information" includes qualifying information not previously submitted to FDA. New analyses of previously submitted data can count when they reveal risks of a different type, greater severity or greater frequency. The definition appears in section 314.3(b).
Changes to the information required in Highlights are excluded from this CBE labeling provision. Paragraph (b)(2)(v)(C) requires prior approval, with two annual-report exceptions: removal of a listed section specified in section 201.57(a)(5), and a change to the most recent revision date under section 201.57(a)(15). Those two may be reported in the annual report. Other Highlights changes stay on the prior-approval route.
Minor changes and the annual report deadline
Minor changes have minimal adverse-effect potential and belong in the next annual report. Section 314.70(d) gives conditional examples:
- Equipment replacement with the same design and operating principles, subject to the stated exception.
- An expiration-period extension supported by full shelf-life production-batch data under an approved protocol.
- Editorial or similarly minor labeling changes.
These examples do not cover all equipment replacements or shelf-life extensions. For minor manufacturing changes, the report needs an assessment statement and a full description, including affected sites or areas. It must also include implementation dates, supporting data and applicable validation-protocol or SOP references. See paragraph (d)(3).
The annual report is due within 60 days of the anniversary date of U.S. approval. It covers the interval ending on that anniversary, rather than a period measured from each change. Manufacturing changes not requiring supplements must appear in implementation-date order. Labeling changes need a dated summary, or a statement that none occurred. Section 314.81(b)(2) sets the deadline and reporting details.
Is an sNDA the same as a PAS?
An sNDA is a supplemental new drug application: a supplement to an NDA. PAS identifies a reporting route. Because section 314.70 provides both prior-approval and CBE supplements, "sNDA" alone does not establish distribution timing. An annual report is not a supplement.
For approved ANDAs, section 314.97(a) requires compliance with sections 314.70 and 314.71 for supplements and other changes. Generic labeling also has sameness requirements. It generally must match the reference listed drug's approved labeling, subject to permitted differences. Those include specified manufacturer differences and protected-labeling omissions under section 314.94(a)(8).
Do not read the NDA CBE labeling provision as unrestricted authority for a generic manufacturer to create different safety labeling independently. Check the applicable ANDA labeling requirements alongside the reporting route.
Use approved protocols and applicable FDA guidance
A comparability protocol can specify tests, studies and acceptance criteria for particular manufacturing changes. An approved protocol may later justify a reduced reporting category for that particular change. It does not reduce the category for every future change. A new protocol, or a change to an approved protocol, requires an approved supplement before distribution of product made with that manufacturing change. These provisions appear in section 314.70(e).
RegAffairs AI provides a citation-backed answer on reporting approved-drug changes and distribution timing.
For product-specific classification, consult the approved application and applicable current FDA guidance. Relevant documents include Changes to an Approved NDA or ANDA, final April 2004, and CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports, final March 2014. Section 10.115(d) keeps guidance nonbinding, but paragraph (a)(3) still requires the less burdensome notice when a regulation or guidance provides one. An alternative approach must meet the applicable statute and regulations.